Ratings by Maxim Group (Naz Rahman)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/24/2026 | NEXGEL | NXGL | Downgrade | Hold (Buy) |
0.33 (0.29) |
-12.12% | Details | |
| 7/29/2026 | Silexion Therapeutics | SLXN | Downgrade | Hold (Buy) |
2.45 (0.36) |
-85.31% | Details | |
| 5/29/2026 | Alpha Cognition Inc | ACOG | New Coverage | Buy (N/A) |
5.94 (8.90) |
49.83% | Details | |
| 4/20/2026 | Xtant Medical | XTNT | New Coverage | Buy (N/A) |
0.48 (0.35) |
-27.08% | Details | |
| 4/9/2026 | Assertio Therapeutics | ASRT | Downgrade | Hold (Buy) |
18.41 (23.50) |
27.65% | Details | |
| 3/18/2026 | Vertex | VRTX | Upgrade | Buy (Hold) |
462.49 (515.44) |
11.45% | Details | |
| 2/24/2026 | Scienture Holdings | SCNX | New Coverage | Buy (N/A) |
0.37 (0.35) |
-5.41% | Details | |
| 12/3/2025 | Clene, Inc. | CLNN | Maintain | Buy (N/A) |
|
Details | ||
| 10/2/2025 | Kazia Therapeutics | KZIA | Maintain | Buy (N/A) |
|
Details | ||
| 9/25/2025 | Aytu Biosciences | AYTU | Maintain | Buy (N/A) |
|
Details | ||
| 8/25/2025 | scPharmaceuticals | SCPH | Downgrade | Hold (Buy) |
4.85 (5.67) |
16.91% | Details | |
| 4/2/2025 | Nuvectis Pharma | NVCT | New Coverage | Buy (N/A) |
9.35 (23.99) |
156.58% | Details | |
| 3/26/2025 | Palisade Bio Inc. | PALI | Maintain | Buy (N/A) |
|
Details | ||
| 3/20/2025 | Silexion Therapeutics | SLXN | Maintain | Buy (N/A) |
|
Details | ||
| 3/20/2025 | scPharmaceuticals | SCPH | Maintain | Buy (N/A) |
|
Details | ||
| 2/6/2025 | Viking Therapeutic | VKTX | Maintain | Buy (N/A) |
|
Details | ||
| 2/6/2025 | Kazia Therapeutics | KZIA | New Coverage | Buy (N/A) |
1.40 (11.19) |
699.29% | Details | |
| 12/16/2024 | NeuroSense Therapeutics Ltd. | NRSN | Downgrade | Hold (Buy) |
0.86 (0.35) |
-59.3% | Details | |
| 11/20/2024 | Cingulate | CING | Upgrade | Buy (Hold) |
4.10 (5.02) |
22.44% | Details | |
| 11/13/2024 | Palisade Bio Inc. | PALI | Maintain | Buy (N/A) |
|
Details | ||
| 11/1/2024 | Silexion Therapeutics | SLXN | New Coverage | Buy (N/A) |
0.30 (2.45) |
716.67% | Details | |
| 10/24/2024 | PainReform Ltd. | PRFX | Downgrade | Hold (Buy) |
0.74 (0.86) |
16.22% | Details | |
| 10/9/2024 | Virpax Pharmaceuticals, Inc. | VRPX | Downgrade | Hold (Buy) |
0.49 (0.67) |
36.73% | Details | |
| 8/9/2024 | Quoin Pharmaceuticals | QNRX | Maintain | Buy (N/A) |
|
Details | ||
| 7/26/2024 | Assertio Therapeutics | ASRT | New Coverage | Buy (N/A) |
1.47 (18.41) |
1152.38% | Details | |
| 7/19/2024 | Virpax Pharmaceuticals, Inc. | VRPX | Upgrade | Buy (Hold) |
1.28 (0.67) |
-47.66% | Details | |
| 6/25/2024 | Alimera Sciences | ALIM | Downgrade | Hold (Buy) |
5.54 (5.54) |
0% | Details | |
| 5/22/2024 | Virpax Pharmaceuticals, Inc. | VRPX | Downgrade | Hold (Buy) |
0.74 (0.67) |
-9.46% | Details | |
| 3/25/2024 | Alimera Sciences | ALIM | New Coverage | Buy (N/A) |
3.98 (5.54) |
39.2% | Details | |
| 3/18/2024 | Agile Therapeutics | AGRX | Downgrade | Hold (Buy) |
0.54 (1.51) |
179.63% | Details | |
| 1/31/2024 | Vertex | VRTX | Downgrade | Hold (Buy) |
446.08 (515.44) |
15.55% | Details | |
| 12/18/2023 | Cingulate | CING | Downgrade | Hold (Buy) |
2.13 (5.02) |
135.68% | Details | |
| 12/8/2023 | Petros Pharmaceuticals Inc. | PTPI | New Coverage | Buy (N/A) |
1.31 (0.07) |
-94.66% | Details | |
| 11/17/2023 | Palisade Bio Inc. | PALI | Upgrade | Buy (Hold) |
0.52 (2.06) |
296.15% | Details | |
| 11/17/2023 | Processa Pharmaceuticals | PCSA | Downgrade | Hold (Buy) |
0.42 (2.08) |
395.24% | Details | |
| 8/9/2023 | Palisade Bio Inc. | PALI | Downgrade | Hold (Buy) |
1.94 (2.06) |
6.19% | Details | |
| 7/12/2023 | Cingulate | CING | Maintain | Buy (N/A) |
|
Details | ||
| 6/8/2023 | Vivani Medical, Inc. | VANI | New Coverage | Buy (N/A) |
1.45 (1.27) |
-12.41% | Details | |
| 5/19/2023 | Processa Pharmaceuticals | PCSA | Maintain | Buy (N/A) |
|
Details | ||
| 5/11/2023 | scPharmaceuticals | SCPH | Maintain | Buy (N/A) |
|
Details | ||
| 5/2/2023 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/30/2023 | Palisade Bio Inc. | PALI | Upgrade | Buy (Hold) |
1.68 (2.06) |
22.62% | Details | |
| 1/12/2023 | Processa Pharmaceuticals | PCSA | Maintain | Buy (N/A) |
|
Details | ||
| 12/19/2022 | Viking Therapeutic | VKTX | Maintain | Buy (N/A) |
|
Details | ||
| 10/11/2022 | scPharmaceuticals | SCPH | Maintain | Buy (N/A) |
|
Details | ||
| 10/4/2022 | Clene, Inc. | CLNN | Maintain | Buy (N/A) |
|
Details | ||
| 8/22/2022 | Clarus | CRXT | Downgrade | Hold (Buy) |
0.21 (0.10) |
-52.38% | Details | |
| 8/19/2022 | Palisade Bio Inc. | PALI | Downgrade | Hold (Buy) |
0.16 (2.06) |
1187.5% | Details | |
| 8/2/2022 | scPharmaceuticals | SCPH | New Coverage | Buy (N/A) |
4.89 (4.85) |
-0.82% | Details | |
| 7/1/2022 | 9 Meter Biopharma | NMTR | Downgrade | Hold (Buy) |
0.26 (0.07) |
-73.08% | Details | |
| 6/21/2022 | 9 Meter Biopharma | NMTR | Maintain | Buy (N/A) |
|
Details | ||
| 6/9/2022 | Virpax Pharmaceuticals, Inc. | VRPX | New Coverage | Buy (N/A) |
1.55 (0.67) |
-56.77% | Details | |
| 5/9/2022 | 180 Life Sciences Corp. | ATNF | Downgrade | Hold (Buy) |
1.31 (7.04) |
437.4% | Details | |
| 4/19/2022 | Processa Pharmaceuticals | PCSA | New Coverage | Buy (N/A) |
2.87 (2.08) |
-27.53% | Details | |
| 2/25/2022 | NEXGEL | NXGL | New Coverage | Buy (N/A) |
1.81 (0.33) |
-81.77% | Details | |
| 1/7/2022 | Quoin Pharmaceuticals | QNRX | New Coverage | Buy (N/A) |
1.74 (6.79) |
290.23% | Details | |
| 1/7/2022 | NeuroSense Therapeutics Ltd. | NRSN | New Coverage | Buy (N/A) |
2.53 (0.35) |
-86.17% | Details | |
| 12/7/2021 | First Wave BioPharma, Inc. | FWBI | Downgrade | Hold (Buy) |
1.40 (2.96) |
111.43% | Details | |
| 10/1/2021 | First Wave BioPharma, Inc. | FWBI | Maintain | Buy (N/A) |
|
Details | ||
| 9/29/2021 | Clarus | CRXT | New Coverage | Buy (N/A) |
5.61 (0.10) |
-98.22% | Details | |
| 9/15/2021 | 180 Life Sciences Corp. | ATNF | New Coverage | Buy (N/A) |
5.67 (7.04) |
24.16% | Details | |
| 8/31/2021 | Palisade Bio Inc. | PALI | New Coverage | Buy (N/A) |
2.73 (2.06) |
-24.54% | Details |
